Physician profile
William Bush
NPI 1982636841
$6,517.46
in general payments reported to CMS, 2019-2025
34 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $1,213 · 2021: $1,456 · 2022: $852 · 2023: $780 · 2024: $1,102 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $652.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $622.64 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Lilly USA, LLC | $601.89 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $570.25 | 2019-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $495.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $465.07 | 2020-2024 | Vraylar, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $350.58 | 2019-2025 | Eliquis, Camzyos |
| Kowa Pharmaceuticals America, INC. | $295.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $293.63 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $228.74 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $200.43 | 2019-2022 | |
| Novo Nordisk INC | $164.30 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.35 | 2020-2022 | |
| Allergan, INC. | $142.13 | 2020 | |
| Mylan Specialty L.P. | $118.90 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $115.16 | 2019-2024 | |
| Ibsa Pharma INC. | $108.98 | 2022-2024 | Tirosint, Licart, Tirosint |
| Merck Sharp & Dohme LLC | $102.84 | 2020-2023 | Verquvo |
| Genentech USA, INC. | $94.31 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $91.80 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $83.44 | 2019-2024 | Rexulti |
| Almatica Pharma LLC | $78.40 | 2022-2023 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $74.34 | 2023-2025 | Quviviq, Quviviq |
| Jazz Pharmaceuticals INC. | $62.34 | 2021 | |
| Paratek Pharmaceuticals, INC. | $58.39 | 2021 | |
| Astellas Pharma US INC | $54.22 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $46.33 | 2021 | |
| Phathom Pharmaceuticals, INC. | $45.70 | 2024 | Voquezna |
| Amgen INC. | $44.91 | 2020-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.97 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.71 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $16.55 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.99 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.